Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC Completed approximately $100 million public offering, extending runway into 2027 Initial data from 12-month ev ...

In December 2024, the Company reported positive interim results from its ongoing Phase 2 open-label ADVANCED-2 trial in in ...

"In addition, we expect to begin the pivotal THRIVE-3 study of intravenous (IV) Choline Chloride in the first half of 2025.

A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time ...

Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "Choline Chloride Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering. The global choline chloride market is ...

(Trospium chloride + xanomeline tartrate) is under clinical development by Bristol-Myers ... The drug candidate act by targeting muscarinic acetyl choline receptors. It was also under development for ...